Eupraxia Pharmaceuticals (EPRX) Price & Analysis

Compare

45 Followers

EPRX Stock Chart & Stats

C$8.63

C$0.00(0.00%)

At close: Jan 08 4:00 PM EST

C$8.63

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$3.96 - C$9.88

Previous CloseN/A

Volume2.50K

Average Volume (3M)53.43K

Market Cap

C$396.50M

Enterprise ValueC$295.74M

Total Cash (Recent Filing)C$123.78M

Total Debt (Recent Filing)C$237.38K

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Mar 31, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding50,598,330

10 Day Avg. Volume45,847

30 Day Avg. Volume53,430

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)3.18

Price to Sales (P/S)0.00

P/FCF Ratio-3.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$17.57

Price Target Upside103.59% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical SuccessThe EP-104GI advanced through key milestones during the quarter, with the highest dose evaluated to date confirming sustained symptom improvement and tissue response following a single administration.

Financial StabilityEupraxia Pharmaceuticals made significant advancements on its pipeline, and its overall spending remained disciplined, supporting the company's view of a cash runway into 2028.

Market OpportunityEoE represents a blockbuster market opportunity, as it is estimated that there could be upwards of 500K+ patients in the US.

Bears Say

Side EffectsThere is a 16% rate of esophageal candidiasis in an 8-week study in 55 patients, and typically quoted at a 5-10% rate by physicians consulted.

Eupraxia Pharmaceuticals News

Promising Prospects for Eupraxia Pharmaceuticals’ EP-104GI in Eosinophilic Esophagitis Treatment

Sam Slutsky, an analyst from LifeSci Capital, has initiated a new Buy rating on Eupraxia Pharmaceuticals (EPRX). Sam...

4d ago

EPRX

Eupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) just unveiled an update. On November 13, 2025, Eupraxia Pharmaceuticals announced additional 52-week...

1M ago

EPRX

Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data

Eupraxia Pharmaceuticals (EPRX) announced the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE...

1M ago

EPRX

Eupraxia Pharmaceuticals: Buy Rating Backed by Strong Pipeline Advancements and Robust Financial Position

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Eupraxia Pharmaceuticals and keeping the price target...

1M ago

EPRX

Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. Eupraxia Pharmaceuticals Inc. released its consolidated financial statements and...

1M ago

EPRX

Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial

Eupraxia Pharmaceuticals, Inc. (($TSE:EPRX)) announced an update on their ongoing clinical study. Study Overview: Eupraxia Pharmaceuticals, Inc. is...

2M ago

EPRX

Eupraxia Pharmaceuticals management to meet virtually with Craig-Hallum

Virtual Meeting to be held on October 29-30 hosted by Craig-Hallum. Published first on TheFly – the ultimate...

2M ago

EPRX

Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results

H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on EPRX stock, giving a Buy rating yesterday....

2M ago

EPRX

Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion

An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On September 29, 2025, Eupraxia Pharmaceuticals announced...

2M ago

EPRX

Closing Bell Movers: Progress Software up 4%, Jefferies slips 1% on earnings

In the opening hour of evening session, U.S. equity futures are modestly lower, with S&P 500, Dow Industrials,...

3M ago

IDT

JEF

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. On September 24, 2025, Eupraxia Pharmaceuticals Inc. announced the...

3M ago

EPRX

Eupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trial

Eupraxia Pharmaceuticals (EPRX) provided an operational update on the development of EP-104GI, including reporting data from patients in...

3M ago

EPRX

Eupraxia Pharmaceuticals Secures $80.5 Million in Public Offering

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an announcement. On September 24, 2025, Eupraxia Pharmaceuticals announced the successful...

3M ago

EPRX

Eupraxia Pharmaceuticals Announces Major Share Offering to Boost Capital

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an announcement. On September 22, 2025, Eupraxia Pharmaceuticals Inc. announced an...

3M ago

EPRX

EPRX FAQ

What was Eupraxia Pharmaceuticals’s price range in the past 12 months?

Eupraxia Pharmaceuticals lowest stock price was C$3.96 and its highest was C$9.88 in the past 12 months.

What is Eupraxia Pharmaceuticals’s market cap?

Eupraxia Pharmaceuticals’s market cap is C$396.50M.

When is Eupraxia Pharmaceuticals’s upcoming earnings report date?

Eupraxia Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 106 days.

How were Eupraxia Pharmaceuticals’s earnings last quarter?

Eupraxia Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -C$0.268 earnings per share for the quarter, missing the consensus estimate of -C$0.249 by -C$0.019.

Is Eupraxia Pharmaceuticals overvalued?

According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eupraxia Pharmaceuticals pay dividends?

Eupraxia Pharmaceuticals does not currently pay dividends.

What is Eupraxia Pharmaceuticals’s EPS estimate?

Eupraxia Pharmaceuticals’s EPS estimate is -0.2.

How many shares outstanding does Eupraxia Pharmaceuticals have?

Eupraxia Pharmaceuticals has 50,598,330 shares outstanding.

What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?

Eupraxia Pharmaceuticals reported an EPS of -C$0.268 in its last earnings report, missing expectations of -C$0.249. Following the earnings report the stock price went up 3.097%.

Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?

Currently, no hedge funds are holding shares in TSE:EPRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Eupraxia Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-59.46%

Trailing 12-Months

Asset Growth

-5.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (EPRX) is a clinical-stage biotechnology company focused on developing innovative drug products for the treatment of chronic diseases. The company's primary focus is on creating long-acting formulations that aim to provide sustained therapeutic effects, particularly in areas with significant unmet medical needs such as osteoarthritis and other pain-related conditions. Eupraxia's lead product candidate is EP-104IAR, a proprietary sustained-release formulation intended to alleviate pain and improve joint function in patients with osteoarthritis.

Eupraxia Pharmaceuticals (EPRX) Earnings & Revenues

Historic Earnings Reports

EPRX Stock 12 Month Forecast

Average Price Target

C$17.57

▲(103.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"C$3","8":"C$8","13":"C$13","18":"C$18","23":"C$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.04880224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$22.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$17.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.15855154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$15.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8,13,18,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.39,9.440677095384617,10.491354190769231,11.542031286153847,12.592708381538461,13.643385476923077,14.694062572307693,15.744739667692308,16.795416763076922,17.84609385846154,18.896770953846154,19.947448049230772,20.998125144615386,{"y":22.04880224,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.39,9.096153846153847,9.802307692307693,10.508461538461539,11.214615384615385,11.920769230769231,12.626923076923077,13.333076923076923,14.03923076923077,14.745384615384616,15.451538461538462,16.157692307692308,16.863846153846154,{"y":17.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.39,8.910657810769232,9.431315621538461,9.951973432307692,10.472631243076924,10.993289053846155,11.513946864615384,12.034604675384616,12.555262486153847,13.075920296923076,13.596578107692308,14.117235918461539,14.637893729230768,{"y":15.15855154,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >